Summary
Other Scenarios:
- MRK - SHPGY
- MRK - ENDP
- SHPGY - KG
- ENDP - KG
| Buyer: | Merck & Co., Inc. (MRK) | Last Price: | 40.00 | Market Cap.: | 87.37B |
|---|---|---|---|---|---|
| Target: | King Pharmaceuticals, Inc. (KG) | Last Price: | 9.18 | Market Cap.: | 2.26B |
Lines of Business Summary:
- Merck & Co., Inc. (MRK) competes in 2 industries and 166 product/service groups
- King Pharmaceuticals, Inc. (KG) competes in 1 industry and 81 product/service groups
- A combined entity will have 2% Product/Service Group overlap
- Merck & Co., Inc. (MRK) has 12 and King Pharmaceuticals, Inc. (KG) has 0 suppliers that rely on a material % of their business. They share 0 in common.
- Merck & Co., Inc. (MRK) has 0 and King Pharmaceuticals, Inc. (KG) has 3 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Consumer |
|
955 | |
Consumer Products and Services |
|
368 | |
|
Healthcare |
|
|
893 |
|
Biopharmaceuticals |
|
|
366 |
|
Medical Devices |
|
241 | |
|
Outsourced Services |
|
66 | |
|
Scientific Products |
|
35 | |
|
Veterinary Products and Services |
|
7 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 144)
|
Target (Total: 65)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 59)
|
Target (Total: 7)
|
Buyer (Total: 9)
|
Target (Total: 9)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 59,800 | 2,050 |
| Revenue Per Employee | 418,725.8 | 1,043,389.0 |
| Total Revenue | 6,242.8 | 533.3 |
| Total Expenses | 9,423.3 | 483.8 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
1,544.8 | 131.8 |
|
SG&A Expense
|
1,719.5 | 164.3 |
|
Research & Development
|
1,381.7 | 44.9 |
|
Other Operating Expense
|
567.4 | 0.0 |
|
Operating Income
|
-3,180.5 | 49.5 |
|
Unusual Income
|
5,006.2 | 81.8 |
|
LT Debt to Capital
|
17.72 | 13.74 |
|
Fwd P/E
|
11.62 | 7.25 |
|
Fwd P/Rev
|
3.38 | 1.39 |
| Book Value | 18,184.7 | 2,510.8 |
|
Curr Portion of LTD/Cap Lease
|
1,823.6 | 0.0 |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Biopharmaceuticals
Target
Focused ():
Healthcare > Biopharmaceuticals
Business Description
Buyer
Merck & Co., Inc. (Merck) is a global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of products to improve human and animal health. The Company?s operations are principally managed on a products basis and comprises of two business segments: the Pharmaceutical segment and the Vaccines segment. The Pharmaceutical segment includes human health pharmaceutical products marketed either directly or through joint ventures. Merck sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Vaccines segment includes human health vaccine products marketed either directly or through a joint venture. These products consist of preventative pediatric, adolescent and adult vaccines, primarily administered at physician offices.
Target
King Pharmaceuticals, Inc. is a vertically integrated pharmaceutical company that performs basic research and develops, manufactures, markets and sells branded prescription pharmaceutical products. The Company?s wholly owned subsidiaries are Monarch Pharmaceuticals, Inc., King Pharmaceuticals Research and Development, Inc., Meridian Medical Technologies, Inc., Parkedale Pharmaceuticals, Inc., King Pharmaceuticals Canada Inc. and Monarch Pharmaceuticals Ireland Limited. The Company markets its branded prescription pharmaceutical products to general/family practitioners, internal medicine physicians, neurologists, pain specialists, surgeons and hospitals across the United States and in Puerto Rico.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
74.62 | 73.49 |
|
Operating Margin %
|
13.93 | 10.65 |
|
Quick Ratio
|
0.97 | 3.47 |
|
Current Ratio
|
1.23 | 4.02 |
|
Coverage Ratio
|
0 | 0.1 |
| Total Assets | 48,350.7 | 3,426.8 |
| Return on Equity % | 18.01 | 7.3 |
| Return on Assets % | 6.77 | 5.35 |
|
Cash+ ST Inv. Per Share
|
3.78 | 5.6 |
| Total Debt | 5,739.4 | 400.0 |
| Total Debt to Equity % | 31.56 | 15.93 |
| Total Debt to Tangible Equity % | 35.83 | 24.99 |
|
Debt to Asset %
|
11.87 | 11.67 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Consumer |
|
|
Consumer Products and Services |
|
|
|
Food, Beverage and Agriculture
Includes agricultural inputs like livestock and crops, as well as processed food and beverage products. Tobacco growers and cigarette manufacturers are also included.
|
|
|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
|
|
|
|
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
|
|
|
|
Medical Devices |
|
|
|
Cardiology
The Cardiology Subsector includes medical devices that diagnose, monitor, and treat diseases affecting the heart and proximal blood vessels. Common devices include vital sign monitors, cardiac defibrillators, pacemakers, and other surgical equipment.
|
|
|
|
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
|
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
|
|
|
|
General Surgery
The General Surgery Subsector includes medical devices that perform general, non-specialty surgeries; these devices are often general in scope and are used in procedures involving various parts of the body.
|
|
|
|
Radiology
The Radiology Subsector includes medical devices that generate images of internal physiology.
|
|
|
|
Outsourced Services |
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Scientific Products |
|
|
|
Analytical Instruments
The Analytical Instruments Subsector includes scientific products that determine the quantitative and qualitative nature of biochemical samples.
|
|
|
|
Bioanalytical Instruments
The Bioanalytical Instruments Subsector includes scientific products, devices and apparatuses that determine the quantitative and qualitative nature of a biological samples.
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
|
|
|
|
Veterinary Services
The Veterinary Services Subsector includes companies that diagnose and treat animal diseases, such as veterinary laboratories, clinics, and hospitals.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Consumer |
|
|
|
Consumer Products and Services |
|
|
Food, Beverage and Agriculture |
|
|
Agriculture |
|
|
|
Animal Production |
|
|
|
Support Activities for Animal Production
Includes food irradiation, animal feed, and other support activities.
Buyer Products:
|
|
|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
|
Allergies |
|
|
|
Systemic |
|
|
|
Anaphylactic Shock |
|
|
|
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that treat allergic shock by stimulating alpha and beta adrenergic receptors.
Target Products:
|
|
|
|
Upper Respiratory |
|
|
|
Antihistamines/Leukotriene Receptor Antagonists
Therapeutics that treat allergic reactions by suppressing inflammation and working on certain receptors involved in the immune process.
Buyer Products:
|
|
|
|
Leukotriene Receptor Antagonists
Therapeutics that treat allergic reactions by working on certain receptors involved in the immune process.
Buyer Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Acute Coronary Syndrome (ACS) |
|
|
|
Cholesterol Absorption Inhibitors (CETP)/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that reduce the incidence of acute coronary syndrome (ACS) by blocking cholesterol synthesis and also inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
Angina |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Arrhythmia |
|
|
|
Adenosine A1 Receptor Agonists
Therapeutics that treat abnormal rhythm of the heart beat by selectively stimulating the A1 adenosine receptor, slowing the speed of AV nodal conduction
Target Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.
Target Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Adenosine A1 Receptor Antagonist
Therapeutics that treat heart failure by blocking the adenosine A1 receptors, thus inhibiting detrimental neuromodulatory effects of adenosine
Buyer Products:
|
|
|
|
Adjunctive Treatments |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that assist in the primary treatment of the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
Target Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
Target Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Vascular Disorders |
|
|
|
Atherosclerosis |
|
|
|
Free Fatty Acid Inhibitors/Prostaglandin Inhibitors/Statins |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Coronary Artery Disease (CAD) |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the coronary arteries of the heart muscle by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Hypertension |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.
Buyer Products:
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
Target Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Stroke |
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that reduce the risk of stroke by reducing high blood pressure through blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that reduce the risk of stroke by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Hair Disorders |
|
|
|
Alopecia (Hair Loss) |
|
|
|
5 Alpha Reductase Inhibitors
Therapeutics that treat hair loss by blocking the action of an enzyme that converts testosterone to a testosterone derivative.
Buyer Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Dermatoses |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)/Antibacterial Agents (Antibiotic)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site, as well as prevent the growth of bacteria.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastric |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Zollinger-Ellison Syndrome |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Abdominal Gas |
|
|
|
Acid Neutralizing Agents/Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat abdominal gas by reducing the acidity of the stomach as well as lowering the surface tension of gas bubbles in the bowels.
Buyer Products:
|
|
|
|
Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat abdominal gas by reducing the surface tension of gas bubbles in the bowels.
Buyer Products:
|
|
|
|
Acid Indigestion/Heartburn |
|
|
|
Acid Neutralizing Agents
Therapeutics that treat heartburn by neutralizing stomach acid.
Buyer Products:
|
|
|
|
Acid Neutralizing Agents/Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat indigestion by neutralizing the stomach acid as well as lowering the surface tension of the gas bubbles in the bowels.
Buyer Products:
|
|
|
|
Acid Neutralizing Agents/H2 Receptor Antagonists
Therapeutics that treat heartburn by neutralizing stomach acid and blocking the action of histamine at the H2 receptors.
Buyer Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.
Buyer Products:
|
|
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Nausea/Vomiting |
|
|
|
Antiemetic Agents
Therapeutics that treat nausea or vomiting by acting locally on the hyperactive gastrointestinal wall.
Target Products:
|
|
|
|
Neurokinin-1 (NK-1) Receptor Antagonists
Therapeutics that prevent or treat nausea and vomiting by inhibiting the neurotransmitter NK-1 (Substance P) from binding to its receptors.
Buyer Products:
|
|
|
|
Liver Disorders |
|
|
|
Cirrhosis |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
Target Products:
|
|
|
|
Wilson`s Disease |
|
|
|
Chelating Agents
Therapeutics that treat Wilson's Disease by binding to and removing copper.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Adrenal Gland Disorders |
|
|
|
Adrenocortical Insufficiency |
|
|
|
Synthetic Adrenocortical Steroids
Therapeutics that treat Adrenocortical Insufficiency by acting on the distal tubules
of the kidney to enhance the reabsorption of sodium ions and to increase the urinary excretion of both potassium and hydrogen ions.
Target Products:
|
|
|
|
Diabetes |
|
|
|
Induced Complications |
|
|
|
Central Diabetes Insipidus |
|
|
|
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.
Target Products:
|
|
|
|
Diabetic Foot Ulcers |
|
|
|
Carbapenems
Therapeutics that treat foot ulcers by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Diabetic Nephropathy |
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disese by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Biguanides/Dipeptidyl Peptidase (DPP) Inhibitors
Therapeutics that control high blood sugar by stimulating the release of insulin and by modifying gastric emptying, insulin secretion, and glucagon secretion.
Buyer Products:
|
|
|
|
Dipeptidyl Peptidase (DPP) Inhibitors
Therapeutics that treat non-insulin dependent diabetes by inhibiting the action of dipeptidyl peptidase, thereby increasing the level of glucagon-like peptide-1 (GLP-1). GLP regulates gastric emptying, insulin secretion, food intake, and glucagon secretion.
Buyer Products:
|
|
|
|
General Hormone Treatments |
|
|
|
Estrogens
Therapeutics that treat hormonal disorders by providing estrogen.
Target Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Gout |
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by selectively blocking cyclooxygenase 2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation preventing cyclooxygenase activity.
Buyer Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive cholesterol level by inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
Cholesterol Absorption Inhibitors (CETP)/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hypercholesterolemia through the dual action of blocking cholesterol synthesis by binding a key enzyme in the synthesis process and also inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
Free Fatty Acid Inhibitors/Prostaglandin Inhibitors
Therapeutics that treat elevated cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking the effect of prostaglandin.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive triglyceride level by inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
Free Fatty Acid Inhibitors/Prostaglandin Inhibitors
Therapeutics that treat elevated cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking the effect of prostaglandin.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Pituitary Gland Disorders |
|
|
|
Pituitary Hyperthyroidism (TSH-Induced) |
|
|
|
Thyroid Hormones
Hormones that affect the rate of cell metabolism and blood calcium levels.
Target Products:
|
|
|
|
Reproductive Disorders |
|
|
|
Hypogonadism |
|
|
|
Female |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Target Products:
|
|
|
|
Menopause |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Thyroid Gland Disorders |
|
|
|
Hyperthyroidism |
|
|
|
Thyroid Hormone Synthesis Inhibitors
Therapeutics that stop the production of thyroid hormones.
Target Products:
|
|
|
|
Hypothyroidism |
|
|
|
Thyroid Hormones
Therapeutics that treat a deficiency in thyroid activity by supplementing thyroid hormones.
Target Products:
|
|
|
|
Hematology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive cholesterol level by inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
Cholesterol Absorption Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hypercholesterolemia through the dual action of blocking cholesterol synthesis by binding a key enzyme in the synthesis process and also inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
Free Fatty Acid Inhibitors/Prostaglandin Inhibitors
Therapeutics that treat elevated cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking the effect of prostaglandin.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive triglyceride level by inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
Free Fatty Acid Inhibitors/Prostaglandin Inhibitors
Therapeutics that treat elevated cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking the effect of prostaglandin.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Thrombocyte (Platelet) Disorders |
|
|
|
Hypoprothrombinemia |
|
|
|
Vitamin K Analogs
Therapeutics that treat the deficiency of coagulation factor II.
Buyer Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Chelating Agents
Therapeutics that treat rheumatoid arthritis by lowering IgM rheumatoid factor and depressing T-cell activity.
Buyer Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Integrase Inhibitors
Therapeutics that help manage HIV by blocking the integration of the HIV virus' genetic material into the host cell.
Buyer Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Aminoglycosides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Target Products:
|
|
|
|
Carbapenems
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.
Target Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
Target Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Dermatoses |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)/Antibacterial Agents (Antibiotics)
Therapeutics that treat bacterial infections of the skin with a steroidal compound and a compound that kills or inhibits the growth of bacteria.
Target Products:
|
|
|
|
Skin/Soft Tissue Infections |
|
|
|
Sulfonamides
Therapeutics that treat specific bacterial infections by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Skin/Soft Tissue Infections |
|
|
|
Sulfonamides
Therapeutics that treat bacterial infections of non-skeletal tissue usually involving fat, muscle, and skin by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Ophthalmology |
|
|
|
Ocular Infections |
|
|
|
Aminoglycosides/Polypeptides
Therapeutics that treat bacterial infections of the eye by inhibiting bacterial protein synthesis and damaging the cell membrane.
Target Products:
|
|
|
|
Aminoglycosides/Polypeptides/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat bacterial infections of the eye by inhibiting bacterial protein synthesis, damaging the cell membrane, and suppressing the full immune response.
Target Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
External Ear Canal Infections |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)/Antibacterial Agents (Antibiotic)
Therapeutics that treat bacterial infections of the external auditory canal with a steroidal compound and by killing or inhibiting the growth of microorganisms.
Target Products:
|
|
|
|
Otitis Media |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the middle ear inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Target Products:
|
|
|
|
Respiratory System |
|
|
|
Bronchitis |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Target Products:
|
|
|
|
Pneumonia |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat inflammation of the lungs caused by bacterial infection by inhibiting folic acid synthesis and bacterial growth.
Target Products:
|
|
|
|
Urology |
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Aminoglycosides
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by inhibiting bacterial protein synthesis.
Target Products:
|
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections of the urinary tract by inhibiting dihydrofolate reductase resulting in decreased bacterial nucleic acid/protein production.
Target Products:
|
|
|
|
Vaccines |
|
|
|
Bacterial |
|
|
|
Single Target |
|
|
|
Haemophilus Influenzae Type B (Hib)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause Haemophilus influenzae type B.
Buyer Products:
|
|
|
|
Streptococcus pneumoniae
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause pneumococcal bacteria.
Buyer Products:
|
|
|
|
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial or viral pathogen.
Buyer Products:
|
|
|
|
Helminthic |
|
|
|
Cutaneous Larva Migrans (Creeping Eruptions) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections of the skin caused by the dog and cat hookworm.
Buyer Products:
|
|
|
|
Onchocerciasis (River Blindness) |
|
|
|
Gamma-Aminobutyric Acid (GABA) Agonists
Therapeutics that treat parasitic infections characterize by worm filled nodules under the skin and itching.
Buyer Products:
|
|
|
|
Strongyloidiasis (Threadworm) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat helminthic infections by disrupting the cell cycle of the worm.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Agonists
Therapeutics that treat parasitic infections of the intestines leading to mild to severe diarrhea.
Buyer Products:
|
|
|
|
Trichinosis |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections of the tissues and intestines caused by consuming infected meat.
Buyer Products:
|
|
|
|
Visceral Larval Migrans |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections caused by the migration of an organism to the extraintestinal tissue.
Buyer Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Broad Spectrum |
|
|
|
Echinocandins
Therapeutics that treat fungal infections by inhibiting the synthesis of a major cell wall component.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Digestive System |
|
|
|
Mucous |
|
|
|
Candidiasis |
|
|
|
Echinocandins
Therapeutics that treat fungal infections due to candidiasis through a broad spectrum fungicidal action.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Protozoal |
|
|
|
Antiprotozoal Agents |
|
|
|
Narrow Spectrum |
|
|
|
Amebiasis |
|
|
|
Aminoglycosides
Therapeutics that treat infections by an amoeba by inhibiting protozoal protein synthesis.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Viral |
|
|
|
DNA Viruses |
|
|
|
Herpesvirus |
|
|
|
Herpes Simplex Type 1 |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA blocking the action of an essential enzyme.
Target Products:
|
|
|
|
Herpes Simplex Type 2 |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by blocking the action of an essential enzyme.
Target Products:
|
|
|
|
RNA Viruses |
|
|
|
Retrovirus |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Integrase inhibitors
Therapeutics that help manage HIV by blocking the integration of the HIV virus' genetic material into the host cell.
Buyer Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Vaccines |
|
|
|
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial and viral pathogens.
Buyer Products:
|
|
|
|
Viral |
|
|
|
Combination |
|
|
|
Measles/Mumps/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles, mumps, and rubella.
Buyer Products:
|
|
|
|
Measles/Mumps/Rubella/Varicella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles, mumps, rubella, and varicella.
Buyer Products:
|
|
|
|
Measles/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles and rubella.
.
Buyer Products:
|
|
|
|
Mumps/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to mumps and rubella.
Buyer Products:
|
|
|
|
Single Target |
|
|
|
Hepatitis A
Therapeutics that prevent or treat viral infections of the liver by producing or artificially increasing immunity to the Hepatitis A virus.
Buyer Products:
|
|
|
|
Hepatitis B
Therapeutics that prevent or treat viral infections of the liver by producing or artificially increasing immunity to the Hepatitis B virus.
Buyer Products:
|
|
|
|
Herpes Zoster (Shingles)
Therapeutics that prevent or treat viral infections that cause shingles in adults.
Buyer Products:
|
|
|
|
Measles
Therapeutics that prevent or treat viral infections characterized by a red rash by producing or artificially increasing immunity to the measles virus.
Buyer Products:
|
|
|
|
Mumps
Therapeutics that prevent or treat viral infections characterized by swelling of salivary glands below the ear by producing or artificially increasing immunity to the mumps virus.
Buyer Products:
|
|
|
|
Papillomavirus
Therapeutics that prevent or treat viral infections characterized by the proliferation of epithelial cells, leading to the formation of warts and possibly other related diseases such as cervical pre-cancers and cervical cancer.
Buyer Products:
|
|
|
|
Rotavirus
Therapeutics that prevent or treat viral infections that cause severe dehydrating diarrhea in children by producing or artificially increasing immunity to the rotavirus.
Buyer Products:
|
|
|
|
Rubella (German Measles)
Therapeutics that prevent or treat viral infections that begin in the lower respiratory tract and lead to a rash by producing or artificially increasing immunity to the rubella virus.
Buyer Products:
|
|
|
|
Varicella-Zoster Virus (Chicken Pox)
Therapeutics that prevent or treat viral infections that cause a blistery red rash by producing or artificially increasing immunity to the Varicella Zoster virus.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Osteoporosis |
|
|
|
Cathepsin K Inhibitors
Therapeutics that treat osteoporosis by inhibiting the formation of cathepsin K, resulting in increased bone mineral density.
Buyer Products:
|
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Target Products:
|
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Buyer Products:
|
|
|
|
Osteoclast Bone Resorption Inhibitors/Vitamin D Analogs
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts and by increasing calcium absorption.
Buyer Products:
|
|
|
|
Paget`s Disease |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.
Buyer Products:
|
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by selectively blocking cyclooxygenase 2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by inhibiting cyclooxygenase activity.
Buyer Products:
|
|
|
|
Osteoarthritis (OA) |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Chelating Agents
Therapeutics that treat rheumatoid arthritis by lowering IgM rheumatoid factor and depressing T-cell activity.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Epilepsy |
|
|
|
Status Epilepticus |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat status epilepticus by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Headaches |
|
|
|
Vascular (Migraine) |
|
|
|
Acute Treatments |
|
|
|
CGRP Receptor Antagonists
Therapeutics that treat vascular/migraine headaches by reducing the release of calcitonin gene-related peptide (CGRP).
Buyer Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat acute migraine by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat vascular/migraine headaches by stimulating the receptor that binds with the neurotransmitter, serotonin.
Buyer Products:
|
|
|
|
Neuromuscular Disorders |
|
|
|
Parkinson`s Disease (PD) |
|
|
|
Adjunctive Treatments |
|
|
|
Cholinergic Receptor Blocking Agents
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by blocking acetylcholine receptors on neurons.
Target Products:
|
|
|
|
Dopamine Receptor Agonists
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on neurons.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Mood Disorders |
|
|
|
Depression |
|
|
|
Tricyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Sleep Disorders |
|
|
|
Insomnia |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Child Birth/Pregnancy |
|
|
|
Induction/Cervical Ripening |
|
|
|
Oxytocic Agents
Therapeutics that induce contractions by increasing the levels of intracellular calcium in the uterine smooth muscle thus mimicking uterine contractions and transiently impeding uterine blood flow.
Target Products:
|
|
|
|
Female Genital Disorders |
|
|
|
Ovarian |
|
|
|
Hypogonadism |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
These are female sex hormones.
Target Products:
|
|
|
|
Vulvovaginal |
|
|
|
Atrophy |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.
Target Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Palliative Agents |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat and manage breast cancer in post-menopausal women by providing female hormones.
Target Products:
|
|
|
|
Endocrinology |
|
|
|
Adrenal Glands |
|
|
|
Pheochromocytoma |
|
|
|
Tyrosine Hydroxylase Inhibitors
Therapeutics that treat adrenal gland tumors that produce epinephrine and norepinephrine by inhibiting the production of epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Leukemia (White Blood Cell Cancer) |
|
|
|
Lymphoid |
|
|
|
Acute |
|
|
|
Lymphocytic |
|
|
|
Asparaginases
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by breaking down asparagine which is necessary for cell survival.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of myeliod cells by interacting with DNA and inhibiting cell division but are not curative.
Buyer Products:
|
|
|
|
Lymphoma (Lymphatic Cancer) |
|
|
|
Cutaneous T-Cell (CTCL) |
|
|
|
Mycosis Fungoides |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage T-Cell lymphomas of the skin by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Histone Deacetylase (HDAC) Inhibitors
Therapeutics that treat and manage T-Cell lymphomas of the skin by inhibiting deacetylation of histone, leading to expression of genes responsible for tumor growth regulation and apoptosis.
Buyer Products:
|
|
|
|
Hodgkin`s Disease |
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage lymphoma characterized by the presence of Reed-Sternberg cells by interacting with DNA and inhibiting cell division but that are not curative.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Bone Cancer |
|
|
|
Ewing`s Sarcoma (Primitive Neuroepithelial Cancer) |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat Ewing's Sarcoma by interacting with DNA.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Mammalian Target Of Rapamycin (mTOR) Inhibitors
Therapeutics that treat and manage metastatic bone cancer by inhibiting signals required for cell cycle progression, cell growth, and proliferation.
Buyer Products:
|
|
|
|
Rhabdomyosarcoma |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat and manage cancers arising from striated muscle by interacting with DNA.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Cervical Cancer |
|
|
|
Localized |
|
|
|
Papillomavirus Vaccines
Therapeutics that are meant to promote an immune response against the Papillomavirus that are involved in the pathogenesis of cervical cancer.
Buyer Products:
|
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
|
Wilm`s Tumor (Nephroblastoma) |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat kidney cancer by interacting with DNA.
Buyer Products:
|
|
|
|
Prostate Cancer |
|
|
|
Palliative Agents |
|
|
|
Estrogens
Therapeutics that treat and manage prostate cancer by inhibiting the secretion of luteinizing hormone and affecting the testes so as to decrease serum concentrations of testosterone but are not curative.
Target Products:
|
|
|
|
Testicular Cancer |
|
|
|
Metastatic |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat testicular cancers that have spread beyond their original tumor site by interacting with DNA.
Buyer Products:
|
|
|
|
Uterine Cancer |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat cancer of the uteris by interacting with DNA.
Buyer Products:
|
|
|
|
Vulvar Cancer |
|
|
|
Squamous Cell Carcinoma |
|
|
|
Papillomavirus Vaccines
Therapeutics that promote an immune response against the Papillomavirus that are involved in the pathogenesis of vaginal and vulvar cancers.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Degenerative Disorders |
|
|
|
Dry Eye |
|
|
|
Lubricants
Therapeutics that wet the eye and lubricate the eye.
Buyer Products:
|
|
|
|
Glaucoma |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that decrease the formation of the fluid of the eye.
Buyer Products:
|
|
|
|
Carbonic Anhydrase Inhibitors
Therapeutics that decrease the formation of the fluid of the eye.
Buyer Products:
|
|
|
|
Carbonic Anhydrase Inhibitors/Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that decrease the formation of the fluid of the eye.
Buyer Products:
|
|
|
|
Irritation/Inflammation |
|
|
|
Antibacterial Agents (Antibiotics)
Therapeutics that treat infections by inhibiting bacterial replication.
Target Products:
|
|
|
|
Antibacterial Agents/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat infections by inhibiting bacterial replication as well as prevent cells that cause inflammation from adhering to the inflammation site.
Target Products:
|
|
|
|
Ocular Hypertension |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that decrease the formation of the fluid of the eye.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Pain Management |
|
|
|
Anesthesia |
|
|
|
General (Systemic) |
|
|
|
Adjunctive |
|
|
|
Acetylcholine Blocking Agents
Therapeutics that inhibit neuromuscular activity by competing with acetylcholine at the cholinergic receptors resulting in neuromuscular blockage.
Target Products:
|
|
|
|
Barbiturates
Therapeutics that result in anesthesia due to a general sedative effect by enhancing the response to gamma aminobutyric acid and decrease excitability by directly suppressing conduction in the brain.
Target Products:
|
|
|
|
Primary |
|
|
|
Barbiturates
Therapeutics that result in anesthesia due to a general sedative effect by enhancing the response to gamma aminobutyric acid and decrease excitability by directly suppressing conduction in the brain.
Target Products:
|
|
|
|
Narcotics |
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Target Products:
|
|
|
|
Non-Narcotics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.
Buyer Products:
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Leukotriene Receptor Antagonists
Therapeutics that treat asthma by reducing inflammation in the lung passages by working on certain receptors involved in the immune process.
Buyer Products:
|
|
|
|
Mast Cell Stabilizers
Therapeutics that treat asthma by inhibiting mast cell degranulation.
Target Products:
|
|
|
|
Bronchitis |
|
|
|
Complications |
|
|
|
Bacterial Infections |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Target Products:
|
|
|
|
Bronchospasm |
|
|
|
Bronchodilators |
|
|
|
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Anticholinergic Agents/Opioids
Therapeutics that treat coughs and colds by relieving pain and fever as well as suppressing cough.
Target Products:
|
|
|
|
Decongestants/Antitussives
Therapeutics that treat coughs and colds by reducing mucous build up and suppressing the cough.
Target Products:
|
|
|
|
Decongestants/Antitussives/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing coughs and helping in the ejection of the mucous.
Target Products:
|
|
|
|
Surgery |
|
|
|
General |
|
|
|
Complications |
|
|
|
Hemorrhage |
|
|
|
Coagulating Agents (Coagulants)
Therapeutics that treat bleeding during a surgical procedure by promoting blood clotting.
Target Products:
|
|
|
|
Oncology |
|
|
|
Endocrinology |
|
|
|
Adrenal Glands |
|
|
|
Tyrosine Hydroxylase Inhibitors
Therapeutics that are used prior to specific surgical procedures to remove high levels of epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Toxicology |
|
|
|
Chemical Poisoning |
|
|
|
Nerve Gas |
|
|
|
Anticholinergic Agents
Therapeutics that treat toxicity due to nerve agent/gas by antagonizing the muscarine-like actions of acetylcholine and other choline esters.
Target Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Prostate |
|
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
|
5-Alpha Reductase Inhibitors
Therapeutics that inhibit the transformation of testosterone into dihydrotestosterone (DHT), a substance that causes enlargement of the prostate.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Neurogenic Bladder Disease |
|
|
|
Cholinergic Agents
Therapeutics that treat bladder dysfunction arising from the malfunction of autonomic nerves that control bladder function with choleinergic agents.
Buyer Products:
|
|
|
|
Kidney (Renal) |
|
|
|
Chronic Renal Failure (CRF) |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
Target Products:
|
|
|
|
Cystinuria |
|
|
|
Chelating Agents
Therapeutics that treat an inherited abnormality of kidney function which results in increased excretion of certain amino acids by forming complexes with these amino acids to decrease their excretion.
Buyer Products:
|
|
|
|
Diabetic Nephropathy |
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disese by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Renal Insufficiency |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that delay or treat kidney disease by inhibiting the renin-angiotensin system.
Target Products:
|
|
|
|
Weight Management |
|
|
|
Obesity |
|
|
|
Cannabinoid Receptor Antagonists
Therapeutics that suppress appetite by blocking endogenous cannabinoid binding to neuronal CB1 receptors.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Wound Management |
|
|
|
Burns |
|
|
|
Complications |
|
|
|
Infections |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Sulfonamides
Therapeutics that treat bacterial infections in injuries caused by fire or excessive heat by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Antifungal Agents |
|
|
|
Sulfonamides
Therapeutics that treat fungal infections in injuries caused by fire or excessive heat by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Medical Devices |
|
|
|
Cardiology |
|
|
|
Diagnostic |
|
|
|
Monitoring |
|
|
|
Monitors |
|
|
|
Electrocardiogram (ECG/EKG) |
|
|
|
Interpretive/Analysis
Specialized electrocardiogram devices that facilitate certain diagnostic functions and analysis.
Target Products:
|
|
|
|
Stress/Exercise Test
Instruments used to evaluate the cardiopulmonary system during exercise.
Target Products:
|
|
|
|
Telemetry |
|
|
|
Telemetry Systems
Complete systems or devices used to facilitate transfer of vitals monitoring data from the patient's site to a central monitor.
Target Products:
|
|
|
|
Clinical Diagnostics |
|
|
|
Immunoassays |
|
|
|
Reagents |
|
|
|
Test Kits |
|
|
|
Bacterial |
|
|
|
Tuberculosis
Immunoassay test kits which quantitatively measure tuberculosis antibody in plasma or serum.
Target Products:
|
|
|
|
Drug Delivery |
|
|
|
Percutaneous (Subcutaneous/Intramuscular/Intravenous) |
|
|
|
Automatic Injectors
Pen-shaped medical devices used to contain and deliver liquid medications to a specified needle depth with a press of a button.
Target Products:
|
|
|
|
General Surgery |
|
|
|
Invasive |
|
|
|
Surgical-Site Treatments |
|
|
|
Sealants |
|
|
|
Hemostatic |
|
|
|
Topical
Topical mixture used when conventional hemostasis procedures are not effective.
Target Products:
|
|
|
|
Radiology |
|
|
|
Nuclear |
|
|
|
Gamma Camera |
|
|
|
Contrast Agents |
|
|
|
Radionuclides |
|
|
|
Adjuncts
Radioactive materials that are introduced to the body for nuclear imaging purposes.
Target Products:
|
|
|
|
Outsourced Services |
|
|
|
Development/Manufacturing Services |
|
|
|
Chemistry Services
Outsourced companies that provide medicinal chemistry, organic synthesis, process research, cGMP synthesis, and analytical services to the biopharmaceutical industry.
Target Products:
|
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
Medical Devices
Contract Manufacturing Organizations that manufacture (and/or design, develop) medical devices and products for other organizations.
Target Products:
|
|
|
|
Pharmaceuticals |
|
|
|
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.
Target Products:
|
|
|
|
Biologics
Active Ingredient Contract Manufacturing Organizations (CMO) that manufacture antibodies, proteins, and genetic materials.
Target Products:
|
|
|
|
Scientific Products |
|
|
|
Analytical Instruments |
|
|
|
Chromatography |
|
|
|
Software
Software designed to facilitate the function and control of liquid chromatography machines.
Buyer Products:
|
|
|
|
Bioanalytical Instruments |
|
|
|
Biomolecular |
|
|
|
Microarray Technology |
|
|
|
Software
Computer programs specified for microarray/biochip technology systems used in the analysis of samples.
Buyer Products:
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
|
|
|
|
Veterinary Services
The Veterinary Services Subsector includes companies that diagnose and treat animal diseases, such as veterinary laboratories, clinics, and hospitals.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Shire plc (ADR)
|
|
n/a | 11,237.178 | 0.00 | 19.78 | 4.61 | 3.83 | n/a | |
|
Biovail Corporation (USA)
|
|
n/a | 1,797.025 | 9.19 | 8.32 | 2.13 | 2.39 | 3.17 | |
|
Sciele Pharma Inc.
|
|
n/a | 737.027 | 16.23 | 10.32 | 1.93 | 1.68 | 85.38 | |
|
MiddleBrook Pharmaceuticals, Inc.
|
|
n/a | 238.296 | 0.00 | -9.74 | 22.78 | n/a | n/a | |
|
Neurocrine Biosciences, Inc.
|
|
n/a | 210.507 | 0.00 | -2.57 | 171.81 | 15.67 | 1.77 | |
|
Vanda Pharmaceuticals Inc.
|
|
n/a | 98.615 | 0.00 | -1.02 | n/a | 2.02 | 1.18 | |
|
Somaxon Pharmaceuticals, Inc.
|
|
n/a | 84.238 | 0.00 | -3.99 | n/a | 8.46 | 2.39 | |
|
Avigen, Inc.
|
|
n/a | 75.316 | 0.00 | -2.32 | n/a | 1.25 | 1.08 | |
|
Achillion Pharmaceuticals, Inc.
|
|
n/a | 62.553 | 0.00 | -2.94 | 15.49 | 6.90 | 2.90 | |
|
BioDelivery Sciences International, Inc.
|
|
n/a | 42.312 | 0.00 | n/a | 209.50 | n/a | n/a | |
|
DOV Pharmaceutical, Inc.
|
|
n/a | 7.753 | 0.57 | n/a | 0.25 | n/a | 0.68 | |
| Buyer | |||||||||
|
Johnson & Johnson
|
|
n/a | 186,001.375 | 17.59 | 14.73 | 3.04 | 2.90 | 12.78 | |
|
Roche Holding Ltd. (ADR)
|
|
n/a | 163,455.599 | 16.51 | 19.02 | 3.49 | 3.93 | 5.01 | |
| Target | |||||||||
|
Shire plc (ADR)
|
|
n/a | 11,237.178 | 0.00 | 19.78 | 4.61 | 3.83 | n/a | |
|
Endo Pharmaceuticals
|
|
n/a | 3,251.675 | 14.30 | 11.91 | 3.00 | 2.55 | 3.13 | |
|
Biovail Corporation (USA)
|
|
n/a | 1,797.025 | 9.19 | 8.32 | 2.13 | 2.39 | 3.17 | |
|
Alpharma Inc.
|
|
n/a | 1,480.206 | 0.00 | 111.46 | 2.05 | 2.05 | 4.07 | |
|
Valeant Pharmaceuticals International
|
|
n/a | 1,209.831 | 0.00 | 21.51 | 1.39 | 1.32 | n/a | |
|
Cubist Pharmaceuticals, Inc.
|
|
n/a | 1,112.004 | 23.10 | 15.23 | 3.77 | 2.85 | 14.63 | |
|
Sciele Pharma Inc.
|
|
n/a | 737.027 | 16.23 | 10.32 | 1.93 | 1.68 | 85.38 | |
|
ZymoGenetics, Inc.
|
|
n/a | 720.582 | 0.00 | -5.06 | 18.73 | 8.25 | 6.28 | |
|
Impax Laboratories Inc.
|
|
n/a | 526.362 | 450.59 | 9.34 | 4.67 | n/a | 8.97 | |
|
ACADIA Pharmaceuticals Inc.
|
|
n/a | 337.239 | 0.00 | -4.75 | 44.63 | 28.21 | 2.96 | |
|
Omrix Biopharmaceuticals, Inc.
|
|
n/a | 268.178 | 22.46 | 21.00 | 4.35 | 3.43 | 2.26 | |
|
MiddleBrook Pharmaceuticals, Inc.
|
|
n/a | 238.296 | 0.00 | -9.74 | 22.78 | n/a | n/a | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Neurogen Corporation
|
|
100.00% | 96.299 | 0.00 | -1.94 | 6.24 | 36.49 | 1.76 | |
|
Ambrilia Biopharma Inc.
|
|
96.80% | 21.584 | 0.00 | n/a | 26.54 | n/a | 2.93 | |
|
Sunesis Pharmaceuticals, Inc.
|
|
46.30% | 57.046 | 0.00 | -1.42 | 5.90 | 3.58 | 1.38 | |
|
Arena Pharmaceuticals, Inc.
|
|
39.50% | 510.418 | 0.00 | -2.46 | 26.40 | 23.23 | 1.32 | |
|
Rigel Pharmaceuticals, Inc.
|
|
23.70% | 702.068 | 0.00 | -7.95 | 55.71 | 54.53 | 8.54 | |
|
Vertex Pharmaceuticals Incorporated
|
|
16.80% | 3,651.037 | 0.00 | -8.73 | 18.35 | 16.44 | 13.46 | |
|
WuXi PharmaTech (Cayman) Inc. (ADR)
|
|
13.70% | 1,362.853 | 40.20 | 32.18 | 10.08 | 5.13 | 5.56 | |
|
Nastech Pharmaceutical Co. Inc.
|
|
13.00% | 70.985 | 0.00 | -1.68 | 3.91 | 3.68 | 1.81 | |
|
VirtualScopics, Inc.
|
|
10.80% | 12.088 | 0.00 | n/a | 2.14 | n/a | 2.37 | |
|
deCODE genetics, Inc.
|
|
3.00% | 89.534 | 0.00 | -1.14 | 2.22 | 1.72 | n/a | |
|
Verenium Corporation
|
|
1.00% | 250.530 | 0.00 | -3.72 | 5.41 | 3.68 | n/a | |
|
Corporate Office Properties Trust
|
|
0.70% | 1,708.666 | 91.31 | 14.92 | 4.17 | 3.97 | 2.39 | |
|
AstraZeneca plc (ADR)
|
|
n/a | 61,325.890 | 10.96 | 9.30 | 2.07 | 1.93 | n/a | |
|
Schering-Plough Corporation
|
|
n/a | 26,136.226 | 0.00 | 10.76 | 2.06 | 1.37 | 58.87 | |
|
Adobe Systems Incorporated
|
|
n/a | 20,371.143 | 25.48 | 22.57 | 5.99 | 5.71 | 14.98 | |
|
Biogen Idec Inc.
|
|
n/a | 19,059.016 | 29.91 | 19.43 | 6.01 | 5.08 | 10.01 | |
|
WPP Group plc (ADR)
|
|
n/a | 14,717.725 | 16.89 | 12.95 | 1.25 | 1.10 | n/a | |
|
Agilent Technologies Inc.
|
|
n/a | 11,575.495 | 19.07 | 17.10 | 2.09 | 1.97 | 4.96 | |
| Target | |||||||||
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 105,870.385 | 12.98 | 9.45 | 2.34 | 2.48 | n/a | |
|
Harte-Hanks, Inc.
|
|
n/a | 930.585 | 10.05 | 10.93 | 0.80 | 0.82 | n/a | |
|
Allscripts Healthcare Solutions, Inc.
|
|
n/a | 616.886 | 30.00 | 20.52 | 2.19 | 1.78 | n/a | |
|
Pain Therapeutics, Inc.
|
|
n/a | 380.159 | 18.72 | 17.87 | 5.76 | 5.99 | 3.66 | |
|
`Acura Pharmaceuticals, Inc.
|
|
n/a | 368.984 | 0.00 | n/a | 57.61 | n/a | 19.71 | |
|
Vascular Solutions, Inc.
|
|
n/a | 98.235 | 0.00 | 20.87 | 1.86 | 1.58 | 7.78 | |
|
Gelita AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Bristol Myers Squibb Co.
|
|
n/a | 43,919.802 | 20.29 | 12.95 | 2.27 | 2.02 | 10.37 | |
|
LG Display Co Ltd. (ADR)
|
|
n/a | 17,089.278 | 12.89 | 12.27 | 1.21 | 1.16 | 2.12 | |
|
AU Optronics Corp. (ADR)
|
|
n/a | 14,511.224 | 27.49 | 5.84 | 1.12 | 0.79 | 1.85 | |
|
Sigma-Aldrich Corporation
|
|
n/a | 7,951.151 | 25.56 | 23.48 | 3.90 | 3.50 | 7.51 | |
|
Biovail Corporation (USA)
|
|
n/a | 1,797.025 | 9.19 | 8.32 | 2.13 | 2.39 | 3.17 | |
|
Crucell N.V. (ADR)
|
|
n/a | 1,092.667 | 0.00 | -31.39 | 3.46 | 2.64 | 2.47 | |
|
Theragenics Corporation
|
|
n/a | 127.262 | 22.58 | n/a | 2.05 | n/a | 1.55 | |
|
Nastech Pharmaceutical Co. Inc.
|
|
n/a | 70.985 | 0.00 | -1.68 | 3.91 | 3.68 | 1.81 | |
|
Metabasis Therapeutics, Inc.
|
|
n/a | 62.129 | 0.00 | -1.81 | 6.89 | 5.21 | 1.94 | |
| Target | |||||||||
|
McKesson Corporation
|
|
32.00% | 15,679.934 | 16.68 | 15.86 | 0.16 | 0.15 | 5.30 | |
|
Cardinal Health, Inc.
|
|
29.00% | 19,566.334 | 12.64 | 14.26 | 0.22 | 0.21 | 15.11 | |
|
AmerisourceBergen Corp.
|
|
13.00% | 6,652.212 | 14.56 | 13.97 | 0.10 | 0.09 | n/a | |
|
Barr Pharmaceuticals, Inc.
|
|
n/a | 5,537.808 | 43.15 | 15.38 | 2.21 | 1.93 | 57.12 | |
|
Salix Pharmaceuticals, Ltd.
|
|
n/a | 333.626 | 40.56 | -5.88 | 1.41 | 1.76 | 3.32 | |
|
QLT Inc. (USA)
|
|
n/a | 280.572 | 0.00 | 25.13 | 2.19 | 2.44 | 2.25 | |
|
Vascular Solutions, Inc.
|
|
n/a | 98.235 | 0.00 | 20.87 | 1.86 | 1.58 | 7.78 | |
|
Merck KGaA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Government - United States
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 105,870.385 | 12.98 | 9.45 | 2.34 | 2.48 | n/a | |
|
Salix Pharmaceuticals, Ltd.
|
|
n/a | 333.626 | 40.56 | -5.88 | 1.41 | 1.76 | 3.32 | |
| Buyer | |||||||||
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 122,737.730 | 11.80 | 11.47 | 2.71 | 2.67 | 16.29 | |
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 105,870.385 | 12.98 | 9.45 | 2.34 | 2.48 | n/a | |
|
AstraZeneca plc (ADR)
|
|
n/a | 61,325.890 | 10.96 | 9.30 | 2.07 | 1.93 | n/a | |
|
Gilead Sciences, Inc.
|
|
n/a | 48,179.585 | 29.83 | 26.91 | 11.39 | 9.42 | 13.92 | |
|
E.I. du Pont de Nemours & Company
|
|
n/a | 44,569.993 | 14.97 | 14.31 | 1.45 | 1.41 | 7.18 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 43,919.802 | 20.29 | 12.95 | 2.27 | 2.02 | 10.37 | |
|
Schering-Plough Corporation
|
|
n/a | 26,136.226 | 0.00 | 10.76 | 2.06 | 1.37 | 58.87 | |
|
Biogen Idec Inc.
|
|
n/a | 19,059.016 | 29.91 | 19.43 | 6.01 | 5.08 | 10.01 | |
| Target | |||||||||
|
Sanofi-Aventis SA (ADR)
|
|
n/a | 105,870.385 | 12.98 | 9.45 | 2.34 | 2.48 | n/a | |
|
Eli Lilly & Co.
|
|
n/a | 59,441.574 | 20.13 | 13.18 | 3.19 | 2.91 | 5.30 | |
|
Wyeth
|
|
n/a | 55,458.079 | 12.01 | 12.26 | 2.48 | 2.50 | 4.05 | |
|
Barr Pharmaceuticals, Inc.
|
|
n/a | 5,537.808 | 43.15 | 15.38 | 2.21 | 1.93 | 57.12 | |
|
Teleflex Incorporated
|
|
n/a | 1,942.433 | 13.26 | 13.04 | 1.00 | 0.80 | n/a | |
|
Pain Therapeutics, Inc.
|
|
n/a | 380.159 | 18.72 | 17.87 | 5.76 | 5.99 | 3.66 | |
|
`Acura Pharmaceuticals, Inc.
|
|
n/a | 368.984 | 0.00 | n/a | 57.61 | n/a | 19.71 | |
|
Salix Pharmaceuticals, Ltd.
|
|
n/a | 333.626 | 40.56 | -5.88 | 1.41 | 1.76 | 3.32 | |
|
QLT Inc. (USA)
|
|
n/a | 280.572 | 0.00 | 25.13 | 2.19 | 2.44 | 2.25 | |
|
Vascular Solutions, Inc.
|
|
n/a | 98.235 | 0.00 | 20.87 | 1.86 | 1.58 | 7.78 | |
|
Palatin Technologies, Inc.
|
|
n/a | 23.005 | 0.00 | -1.93 | 1.49 | 1.86 | 1.47 | |
|
Astellas Pharma Inc.
|
|
n/a | 0.000 | 0.00 | n/a | 0.00 | n/a | n/a | |
|
Gelita AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Merck KGaA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
United Research Laboratories and Mutual Pharmaceutical Company
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 24,197.7 | 2,136.9 | 26,334.6 |
|
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 24,197.7 | 2,136.9 | 26,334.6 |
|
Cost of Revenue
|
6,140.7 | 566.5 | 6,707.2 |
|
SG&A Expense
|
7,556.7 | 691.0 | 8,247.7 |
|
Depreciation & Amortization
|
0.0 | 173.9 | 173.9 |
|
Research & Development
|
4,882.8 | 149.4 | 5,032.2 |
|
Interest Expense
|
-2,976.5 | 0.0 | -2,976.5 |
|
Other Operating Expense
|
46.2 | 0.0 | 46.2 |
|
Unusual Expense (Income)
|
5,177.1 | 328.5 | 5,505.6 |
| Total Expenses | 20,827.0 | 1,909.4 | 22,736.4 |
|
Operating Income
|
3,370.7 | 227.5 | 3,598.2 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
0.0 | 23.1 | 23.1 |
|
Other, Net
|
0.0 | 0.2 | 0.2 |
| Income Before Taxes | 3,370.7 | 250.8 | 3,621.5 |
| Income Taxes | 95.3 | 67.6 | 162.9 |
| Income After Taxes | 3,275.4 | 183.2 | 3,458.6 |
|
Net Income - Excl. Xord. Items
|
3,275.4 | 183.2 | 3,458.6 |
| Discontinued Operations | 0.0 | -0.2 | -0.2 |
|
Net Income - Incl. Xord. Items
|
3,275.4 | 183.0 | 3,458.4 |
|
Income Avail. to Common
|
3,275.4 | 183.0 | 3,458.4 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
2,177.7 | 243.2 | 2,420.9 |
|
Basic EPS - Excl. Xord. Items
|
1.50 | 0.75 | 1.43 |
|
Basic EPS - Incl. Xord. Items
|
1.50 | 0.75 | 1.43 |
| Full Dilution Adjustment | 0.0 | 0.0 | 0.0 |
| Fully Diluted Shares Outstanding | 2,177.7 | 244.1 | 2,421.8 |
|
F.D. EPS - Excl. Xord. Items
|
1.50 | 0.75 | 1.43 |
|
F.D. EPS - Incl. Xord. Items
|
1.50 | 0.75 | 1.43 |
| Dividends Per Common Share | 1.52 | 0.00 | 1.52 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
5,336.1 | 20.0 | 5,356.1 |
|
ST Investments
|
2,894.7 | 1,346.1 | 4,240.8 |
|
Accounts Receivable
|
3,636.2 | 203.8 | 3,840.0 |
|
Inventory
|
1,881.0 | 110.3 | 1,991.3 |
|
Prepayments and Advances
|
1,297.4 | 39.2 | 1,336.6 |
|
Other Current Assets
|
0.0 | 100.1 | 100.1 |
|
Current Assets
|
15,045.4 | 1,819.7 | 16,865.1 |
|
PPE
|
24,803.1 | 0.0 | 24,803.1 |
|
Accum D&A
|
-12,457.1 | 0.0 | -12,457.1 |
|
PPE, Net
|
12,346.0 | 257.1 | 12,603.1 |
| Goodwill & Intangibles | 2,168.0 | 910.1 | 3,078.1 |
| Long Term Investments | 7,159.2 | 0.0 | 7,159.2 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
11,632.1 | 440.0 | 12,072.1 |
| Total Assets | 48,350.7 | 3,426.8 | 51,777.5 |
| Liabilities | |||
| Accounts Payable | 624.5 | 76.5 | 701.0 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 8,534.9 | 376.6 | 8,911.5 |
|
ST Debt
|
0.0 | 0.0 | 0.0 |
|
Curr Port of LTD & Cap Lease Oblg
|
1,823.6 | 0.0 | 1,823.6 |
| Other (Current) Liabilities | 1,275.2 | 0.0 | 1,275.2 |
|
Current Liab.
|
12,258.2 | 453.1 | 12,711.3 |
|
LT Debt
|
3,915.8 | 400.0 | 4,315.8 |
|
Total LT Debt
|
3,915.8 | 400.0 | 4,315.8 |
| Minority Interest (BS) | 2,406.7 | 0.0 | 2,406.7 |
| Deferred Taxes | 11,585.3 | 0.0 | 11,585.3 |
|
Other LT Liab.
|
0.0 | 63.0 | 63.0 |
|
Total Liabilities
|
30,166.0 | 916.1 | 31,082.1 |
| Shareholders Equity | |||
| Common Stock | 29.8 | 1,283.4 | 1,313.2 |
| Additional Paid in Capital | 8,014.9 | 0.0 | 8,014.9 |
| Retained Earnings | 39,140.8 | 1,225.4 | 40,366.2 |
| Treasure Stock | -28,174.7 | 0.0 | -28,174.7 |
| Other Equity | -826.1 | 2.0 | -824.1 |
|
Total Equity
|
18,184.7 | 2,510.8 | 20,695.5 |
|
Total Liab. & Equity
|
48,350.7 | 3,426.8 | 51,777.5 |
|
Shares Outstanding
|
2,172.5 | 245.9 | 2,418.4 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | -105.3 | 0.0 | -105.3 |
| CF Depreciation | 987.7 | 0.0 | 987.7 |
| CF Deferred Taxes | -1,703.9 | 0.0 | -1,703.9 |
| Other Non-Cash Items | 5,414.0 | 0.0 | 5,414.0 |
| Change in Working Capital | 781.2 | 672.6 | 1,453.8 |
| Total Cash From Operating Activities | 5,373.7 | 672.6 | 6,046.3 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -537.9 | -148.5 | -686.4 |
| Other Investing Cash Flows | -380.1 | -627.7 | -1,007.8 |
| Total Cash From Investing Activities | -918.0 | -776.3 | -1,694.3 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -1,655.5 | 0.0 | -1,655.5 |
| Purchase Or Sale of Stock | -388.5 | 10.7 | -377.8 |
| Purchase and Retirement of Debt | -685.0 | 0.0 | -685.0 |
| Other Financing Cash Flow | 69.4 | -0.8 | 68.6 |
| Total Cash From Financing Activities | -2,659.6 | 9.8 | -2,649.8 |
| Exchange Rate Effects | 70.5 | 0.0 | 70.5 |
| Net Change in Cash | 1,866.6 | -93.8 | 1,772.8 |
| Cash Taxes Paid | 3,500.0 | 171.9 | 3,671.9 |
| Cash Interest Paid | 182.8 | 6.0 | 188.8 |